Advertisement
Advertisement
U.S. Markets open in 2 hrs 47 mins
Advertisement
Advertisement
Advertisement
Advertisement

Aquestive Therapeutics, Inc. (AQST)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
1.1100-0.0400 (-3.48%)
At close: 04:00PM EDT
1.1000 -0.01 (-0.90%)
After hours: 07:08PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close1.1500
Open1.1200
Bid0.0000 x 1000
Ask0.0000 x 2900
Day's Range1.0900 - 1.1500
52 Week Range0.6180 - 6.4000
Volume395,256
Avg. Volume888,256
Market Cap44.582M
Beta (5Y Monthly)3.43
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Aquestive Therapeutics Enters License and Supply Agreement with Pharmanovia for Libervant™ (diazepam) Buccal Film for European and MENA Markets

    WARREN, N.J., Sept. 28, 2022 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive”), a pharmaceutical company advancing medicines to solve patients’ problems with current standards of care and provide transformative products to improve their lives, today announced it has entered a license, and supply agreement for Libervant™ (diazepam) Buccal Film with Pharmanovia, a global lifecycle management healthcare company, for treatment of prolonged or acute, convulsive seizures in

  • GlobeNewswire

    Aquestive Therapeutics Announces Positive EPIPHAST II Trial Data for AQST-109 When Compared to EpiPen®

    AQST-109 median time to maximum concentration (Tmax) of 12 minutes was faster than EpiPen® Tmax of 22.5 minutesAQST-109 repeat dosing provided significantly higher drug plasma concentrations with a Tmax of 8 minutes after administrationChanges in systolic blood pressure and heart rate were similar after a single dose of AQST-109 when compared to a single dose of EpiPenEnd-of-Phase 2 meeting with FDA scheduled for fourth quarter 2022 and remaining clinical studies will commence thereafterCompany

  • GlobeNewswire

    Aquestive Therapeutics Announces Expert Allergy Scientific Advisory Board

    WARREN, N.J., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing medicines to solve patients' problems with current standards of care and provide transformative products to improve their lives, announced today the establishment of a Scientific Advisory Board comprised of eight allergy experts. “We are very pleased to welcome these leading experts to our Scientific Advisory Board,” said Dan Barber, Chief Executive Officer of Aquestiv

Advertisement
Advertisement